Drugs / CD34+ cells transduced with ADA retrovir
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00018018 | Jun 2001 → Sep 2014 | severe combined immunodeficiency | National Human Genome Research Institute (NHGRI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD34+ cells transduced with ADA retrovir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00018018 ↗ |
| Route | Intravenous | “reinfused into the patient through a peripheral vein” NCT00018018 ↗ |
| Target | ADA | “the human adenosine deaminase (ADA) gene” NCT00018018 ↗ |